A Phenomap of TTR Amyloidosis to Aid Diagnostic Screening
ESC Heart Failure · 01.04.2025 · 12 (2) · 1113-1118
DOI: 10.1002/ehf2.15143 ↗Kurz gefasst
Übersichtsarbeit in der Zeitschrift ESC Heart Failure, online erschienen am 31.10.2024. Verfasst von Alexios S Antonopoulos und 4 weiteren Autor:innen. Beteiligte Einrichtung: Cardiogenetics Unit, 1st Cardiology Department, Hippokration Hospital, National and Kapodistrian University of Athens, Athens, Greece. Hauptthemen laut MEDLINE: Amyloid Neuropathies, Familial, Prealbumin, Cardiomyopathies, Mutation. Die Arbeit wurde bisher 10-mal zitiert (Crossref) und nennt 28 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC 4.0).
Abstract (Originalsprache)
Cardiac amyloidosis due to transthyretin (ATTR) remains an underdiagnosed cause of cardiomyopathy. As awareness of the disease grows and referrals for ATTR increase, clinicians are likely to encounter more atypical forms of the condition in clinical practice. Therefore, physicians and treating cardiologists should be aware of the full phenotypic spectrum of ATTR. The phenotypic manifestation of ATTR varies depending on the stage of the disease, the presence and type of TTR mutation and the patient's comorbidities. ATTR findings can be grouped into four major categories: clinical profile and cardiac phenotype, extra-cardiac findings, electrocardiogram and imaging findings, which cumulatively form the full phenomap of ATTR. Results from any diagnostic test for ATTR should be interpreted in light of the pre-test probability for the disease. Findings that suggest negative markers for ATTR can point towards other forms of amyloidosis (such as AL amyloidosis) or alternate causes of left ventricular hypertrophy, including hypertrophic cardiomyopathy or Fabry disease. The rising number of referrals for ATTR cardiomyopathy presents a challenge in daily clinical practice. To prevent an increase in false-positive diagnostic test results, an ATTR phenomap can serve as a valuable tool for guiding diagnostic assessments, interpreting test outcomes and prioritizing appropriate referrals for ATTR screening.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Cardiogenetics Unit, 1st Cardiology Department, Hippokration Hospital, National and Kapodistrian University of Athens, Athens, Greece.
Zitieren
APA
Antonopoulos, A. S., Tsampras, T., Lazaros, G., Tsioufis, K., & Vlachopoulos, C. (2025). A Phenomap of TTR Amyloidosis to Aid Diagnostic Screening. ESC Heart Failure, 12(2), 1113-1118. https://doi.org/10.1002/ehf2.15143
Vancouver
Antonopoulos AS, Tsampras T, Lazaros G, Tsioufis K, Vlachopoulos C. A Phenomap of TTR Amyloidosis to Aid Diagnostic Screening. ESC Heart Failure. 2025;12(2):1113-1118. doi:10.1002/ehf2.15143
BibTeX
@article{Antonopoulos2025,
author = {Antonopoulos, Alexios S and Tsampras, Theodoros and Lazaros, George and Tsioufis, Konstantinos and Vlachopoulos, Charalambos},
title = {A Phenomap of TTR Amyloidosis to Aid Diagnostic Screening},
journal = {ESC Heart Failure},
year = {2025},
volume = {12},
number = {2},
pages = {1113--1118},
doi = {10.1002/ehf2.15143}
}
EUVIMED